Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...
AnaptysBio (NASDAQ:ANAB) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...
7mon
Investor's Business Daily on MSNAnaptysBio Surges After Sanofi Takes A Stake In $100 Million OfferingAnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma ...
Hosted on MSN1mon
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps NeutralOn Thursday, H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock.
JPMorgan raised the firm’s price target on AnaptysBio (ANAB) to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...
Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes rosnilimab’s positive data in rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results